Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries

Low- and middle-income countries face a high burden of typhoid and paratyphoid fever due to poor water quality and inadequate sanitation. The World Health Organization (WHO) recommends the use of typhoid conjugate vaccines (TCV) in endemic settings and Gavi, the Vaccine Alliance, supports TCV introduction. There are currently 2 WHO-prequalified TCVs with Typbar TCV introduced in Pakistan, Liberia, and Zimbabwe. Countries should assess disease burden and consider introduction of TCV for programmatic use. Several paratyphoid vaccine candidates are in early stages of development. An effective bivalent vaccine would be the most efficient way to control typhoid and paratyphoid fever.

Automated summary

Low- and middle-income countries have a high burden of typhoid and paratyphoid fever due to poor water quality and inadequate sanitation. WHO recommends TCV and Gavi supports its introduction, with 2 WHO-prequalified TCVs currently available. Considering disease burden, countries should assess and consider introducing TCV for programmatic use.